
‘New possibilities for Envlo confirmed beyond blood sugar lowering, expanding its therapeutic area’
Daewoong Pharmaceutical's SGLT-2 inhibitor, Envlo (enavogliflozin), has shown promise as a treatment option for metabolic diseases, offering possibilities beyond simply lowering blood sugar. According to the results of a phase 3 clinical trial analysis …